Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. / Kappos, Ludwig; Bates, David; Edan, Gilles; Eraksoy, Mefkûre; Garcia-Merino, Antonio; Grigoriadis, Nikolaos; Hartung, Hans-Peter; Havrdová, Eva; Hillert, Jan; Hohlfeld, Reinhard; Kremenchutzky, Marcelo; Lyon-Caen, Olivier; Miller, Ariel; Pozzilli, Carlo; Ravnborg, Mads; Saida, Takahiko; Sindic, Christian; Vass, Karl; Clifford, David B; Hauser, Stephen; Major, Eugene O; O'Connor, Paul W; Weiner, Howard L; Clanet, Michel; Gold, Ralf; Hirsch, Hans H; Radü, Ernst-Wilhelm; Sørensen, Per Soelberg; King, John.

In: Lancet Neurology, Vol. 10, No. 8, 2011, p. 745-58.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kappos, L, Bates, D, Edan, G, Eraksoy, M, Garcia-Merino, A, Grigoriadis, N, Hartung, H-P, Havrdová, E, Hillert, J, Hohlfeld, R, Kremenchutzky, M, Lyon-Caen, O, Miller, A, Pozzilli, C, Ravnborg, M, Saida, T, Sindic, C, Vass, K, Clifford, DB, Hauser, S, Major, EO, O'Connor, PW, Weiner, HL, Clanet, M, Gold, R, Hirsch, HH, Radü, E-W, Sørensen, PS & King, J 2011, 'Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring', Lancet Neurology, vol. 10, no. 8, pp. 745-58. https://doi.org/10.1016/S1474-4422(11)70149-1

APA

Kappos, L., Bates, D., Edan, G., Eraksoy, M., Garcia-Merino, A., Grigoriadis, N., Hartung, H-P., Havrdová, E., Hillert, J., Hohlfeld, R., Kremenchutzky, M., Lyon-Caen, O., Miller, A., Pozzilli, C., Ravnborg, M., Saida, T., Sindic, C., Vass, K., Clifford, D. B., ... King, J. (2011). Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, 10(8), 745-58. https://doi.org/10.1016/S1474-4422(11)70149-1

Vancouver

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology. 2011;10(8):745-58. https://doi.org/10.1016/S1474-4422(11)70149-1

Author

Kappos, Ludwig ; Bates, David ; Edan, Gilles ; Eraksoy, Mefkûre ; Garcia-Merino, Antonio ; Grigoriadis, Nikolaos ; Hartung, Hans-Peter ; Havrdová, Eva ; Hillert, Jan ; Hohlfeld, Reinhard ; Kremenchutzky, Marcelo ; Lyon-Caen, Olivier ; Miller, Ariel ; Pozzilli, Carlo ; Ravnborg, Mads ; Saida, Takahiko ; Sindic, Christian ; Vass, Karl ; Clifford, David B ; Hauser, Stephen ; Major, Eugene O ; O'Connor, Paul W ; Weiner, Howard L ; Clanet, Michel ; Gold, Ralf ; Hirsch, Hans H ; Radü, Ernst-Wilhelm ; Sørensen, Per Soelberg ; King, John. / Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. In: Lancet Neurology. 2011 ; Vol. 10, No. 8. pp. 745-58.

Bibtex

@article{f7e21ec16da948d5a566e81e04e75a3c,

title = "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring",

abstract = "Natalizumab, a highly specific a4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.",

author = "Ludwig Kappos and David Bates and Gilles Edan and Mefk{\^u}re Eraksoy and Antonio Garcia-Merino and Nikolaos Grigoriadis and Hans-Peter Hartung and Eva Havrdov{\'a} and Jan Hillert and Reinhard Hohlfeld and Marcelo Kremenchutzky and Olivier Lyon-Caen and Ariel Miller and Carlo Pozzilli and Mads Ravnborg and Takahiko Saida and Christian Sindic and Karl Vass and Clifford, {David B} and Stephen Hauser and Major, {Eugene O} and O'Connor, {Paul W} and Weiner, {Howard L} and Michel Clanet and Ralf Gold and Hirsch, {Hans H} and Ernst-Wilhelm Rad{\"u} and S{\o}rensen, {Per Soelberg} and John King",

year = "2011",

doi = "http://dx.doi.org/10.1016/S1474-4422(11)70149-1",

language = "English",

volume = "10",

pages = "745--58",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "TheLancet Publishing Group",

number = "8",

}

RIS

TY - JOUR

T1 - Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

AU - Kappos, Ludwig

AU - Bates, David

AU - Edan, Gilles

AU - Eraksoy, Mefkûre

AU - Garcia-Merino, Antonio

AU - Grigoriadis, Nikolaos

AU - Hartung, Hans-Peter

AU - Havrdová, Eva

AU - Hillert, Jan

AU - Hohlfeld, Reinhard

AU - Kremenchutzky, Marcelo

AU - Lyon-Caen, Olivier

AU - Miller, Ariel

AU - Pozzilli, Carlo

AU - Ravnborg, Mads

AU - Saida, Takahiko

AU - Sindic, Christian

AU - Vass, Karl

AU - Clifford, David B

AU - Hauser, Stephen

AU - Major, Eugene O

AU - O'Connor, Paul W

AU - Weiner, Howard L

AU - Clanet, Michel

AU - Gold, Ralf

AU - Hirsch, Hans H

AU - Radü, Ernst-Wilhelm

AU - Sørensen, Per Soelberg

AU - King, John

PY - 2011

Y1 - 2011

N2 - Natalizumab, a highly specific a4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.

AB - Natalizumab, a highly specific a4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.

U2 - http://dx.doi.org/10.1016/S1474-4422(11)70149-1

DO - http://dx.doi.org/10.1016/S1474-4422(11)70149-1

M3 - Journal article

VL - 10

SP - 745

EP - 758

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 8

ER -

ID: 40198112

Forskning